Background: Patients can avoid surgical site infections (SSIs), which are a known cause of morbidity and death. They follow between 10 and 35 percent of gynecologic oncology operations performed globally. Objective: To assess how bundled therapies affect the reduction of SSI following gynecologic cancer surgery. Patients and methods: Between January and December 2019, a tertiary university hospital conducted a single-center open-labeled randomised clinical study. Fifty women with gynecological cancer procedures were recruited in the trial and were randomly assigned in a 1:1 ratio to either bundled care (group I) or normal hospital care (group II). Overall surgery site infection was the main result, while duration of hospital stays and readmissions were the secondary results, etc.  Results: The overall infection rate was 20% in group I and 64% in group II (p= 0.002). The length of hospital stays; was 4.68 ± 3.437 days in group I and 8.48 ±7.171 days in group II (P= .021). Conclusion: Significant decreases in SSIs and length of hospital stays following major gynecologic cancer surgery were linked to the SSI reduction bundle. Recommendations: Implementation of the bundled interventions in gynecologic oncology patients as a routine care and further studies are needed to generalize the results of the current study.